Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials.
Huang H et al. Leuk Res. 2014 Jun 30. pii: S0145-2126(14)00188-X. doi: 10.1016/j.leukres.2014.06.009. [Epub ahead of print].
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB et al. Br J Haematol. 2014 Jun 30. doi: 10.1111/bjh.13004. [Epub ahead of print].
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome.
Roussel M et al. J Clin Oncol. 2014 Jul 14. pii: JCO.2013.54.8164. [Epub ahead of print].
The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation-a single institutional experience in Taiwan.
Huang TC et al. Ann Hematol. 2014 Jul 23. [Epub ahead of print].
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation.
Sharma M et al. Biol Blood Marrow Transplant. 2014 Jul 18. pii: S1083-8791(14)00439-X. doi: 10.1016/j.bbmt.2014.07.013. [Epub ahead of print].
Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.
Garfall AL et al. Bone Marrow Transplant. 2014 Jul 21. doi: 10.1038/bmt.2014.153. [Epub ahead of print].
Long-term results of the gimema vel-03-096 trial in mm patients receiving vtd consolidation after asct: mrd kinetics impact on survival.
Ferrero S et al. Leukemia. 2014 Jul 16. doi: 10.1038/leu.2014.219. [Epub ahead of print].
First line and salvage therapy with total therapy 3-based treatment for multiple myeloma–An extended single center experience.
Muchtar E et al. Leuk Res. 2014 Jul 10. pii: S0145-2126(14)00203-3. doi: 10.1016/j.leukres.2014.06.024. [Epub ahead of print].